Senolytics Lack Cell-Type Specificity, Causing Off-Target Toxicity

Senescent 'zombie cells' accumulate with age and poison surrounding tissue. Drugs that kill them (senolytics) show dramatic benefits in mice, but current drugs like dasatinib+quercetin are repurposed cancer drugs that also damage healthy cells — particularly platelets and immune cells — leading to inconsistent clinical results.

Senescent cells are heterogeneous — they arise from different triggers (replication, oncogene activation, DNA damage) and express different surface markers and SASP profiles by tissue. Current senolytics (dasatinib+quercetin, navitoclax, fisetin) target BCL-2 family anti-apoptotic pathways also used by healthy cells. Navitoclax causes severe thrombocytopenia. A 2025 pilot study of D+Q in mild cognitive impairment showed safety but only subtle cognitive improvements. A separate NIA-funded study showed 'subtle impact on age-related bone health in women.'

Why It Matters

Unity Biotechnology's UBX0101 failed Phase 2 in 2020 for osteoarthritis, highlighting the translational gap. IPF affects ~100,000 in the US (3-5 year median survival). Osteoarthritis affects 32.5M Americans. The ARPA-H PROSPR program is now funding human senolytic-adjacent trials.

Startup Approach

Develop targeted senolytics using antibody-drug conjugates or LNP-delivered gene circuits that activate cell death only in cells expressing specific senescence markers (e.g., p16INK4a above threshold AND uPAR surface expression). Start with a narrow indication (IPF or diabetic kidney disease) where senescent cell burden is high and measurable.

NIH Funding

NIA funds the Translational Geroscience Network including senolytic trials. NIH Reporter shows $200M+ in active grants mentioning senescence/senolytic. NCI also funds due to cancer connections.

Who's Working On It

Unity Biotechnology (foselutoclax/UBX1325 for ophthalmology), Rubedo Life Sciences (ML-based senescent cell surface markers), Senisca (RNA-based senotherapeutics), James Kirkland (Mayo Clinic, D+Q trials), Oisin Biotechnologies (gene therapy approach)